The control group (n ϭ 30) consisted of 20 persons with subjective memory complaints, who had undergone the same battery of examinations as the patients; 5 spouses of patients; 3 individuals with a positive family history for AD, all without memory complaints; 1 patient with a suspicion of intracranial hypertension; and 1 patient with a possible neuritis vestibularis. No controls developed dementia within 1 year. The Mini Mental State Examination (MMSE) score (12 ) was used as a measure of global cognitive impairment. The study was approved by the ethics review board of the VUMC. All patients and controls gave written informed consent.
CSF was collected and stored as described previously (4 ) . The albumin ratio (serum albumin/CSF albumin) was used as a measurement of the intactness of the bloodbrain barrier. Except for 1 FTLD patient and 2 controls, the blood-brain barriers of the patients were intact ( Table 1) .
The INNOTEST TM ␤-AMYLOID (1-42) (Innogenetics) uses mAb 21F12, which binds the COOH terminus of the A␤ 42 peptide (amino acids 36 -42), as capture antibody and biotinylated mAb 3D6, which binds the NH 2 terminus (amino acids 1-6), as detection antibody (6 ) . A␤ (1-42) peptides from Bachem were used for calibration. This test was performed at the Department of Clinical Chemistry, VUMC, Amsterdam.
The sandwich ELISA for A␤ (N-42) uses the commercially available mAb 6E10 (Signet Labs), specific to an epitope covering N-terminal amino acid residues 1-17 of A␤ 42, as capture antibody and the polyclonal antibody R165 as detector antibody. R165 was made by immunizing rabbits with conjugated A␤ 33-42 peptides (Ana Spec). A␤ (1-42) from Bachem was used for calibration, although production procedures for the calibrators were slightly different between the 2 laboratories. This test was performed at the New York site according to an in-house protocol.
For statistical analysis, we used SPSS (Ver. 11.0). Passing and Bablok regression analyses (13 ) were performed with Medcalc, Ver. 4.30 (Medcalc Software), and we also prepared a Bland-Altman plot (14 ) . For group differences, we applied the Kruskal-Wallis test, followed by the Mann-Whitney U-test applying the Bonferroni correction. The 2 test with continuity correction was used to test group differences within genders.
The sensitivities and specificities for CSF A␤ (1-42) and A␤ (N-42) were calculated. Cut points corresponded with a sensitivity Ն85% (15 ), but if a higher sensitivity was obtained for a reasonable specificity, it was used. ROC curves were constructed, and the areas under the curves (AUCs) were calculated and compared (16 ) . Spearman correlations were calculated. A test was considered significant at P Ͻ0.05. All reported tests are 2-tailed unless stated otherwise.
The CSF A␤ (1-42) and A␤ (N-42) concentrations were not statistically significantly different (Table 1 and Figs. 1 and 2 in the Data Supplement that accompanies the online version of this Technical Brief at http://www.clinchem. org/content/vol51/issue6/). Concentrations of both CSF A␤ (1-42) and A␤ (N-42) were significantly lower in AD patients than in patients with FTLD and in controls ( Table  1) . CSF A␤ (1-42) concentrations differed significantly between FTLD patients and controls, whereas CSF A␤ (N-42) concentrations did not differ significantly between the 2 groups ( Table 1 ). The ratio of A␤ (1-42) to A␤ (N-42) differed significantly only between the AD and FTLD patient groups.
ROC curves for CSF A␤ (1-42) and A␤ (N-42) are shown in Fig. 1 . In AD patients vs controls, the sensitivity and specificity for CSF A␤ (1-42) were 90% and 93%, respectively at 473 ng/L and for CSF A␤ (N-42), they were 90% and 87%, respectively, at 383 ng/L. The AUCs were not different ( We found no significant correlation of either CSF A␤ (1-42) or A␤ (N-42) with albumin ratio, MMSE score, age, or disease duration (AD and FTLD) in either group.
The absolute concentrations of CSF A␤ (1-42) and A␤ (N-42) were comparable. However, in earlier studies, concentrations of CSF A␤ (N-42) ranged from 36 to 623 ng/L in AD patients and from 111 to 629 ng/L in controls (8, 17, 18 ) . The reason for the low CSF A␤ (N-42) concentrations measured in these studies could be a difference in the affinity of the A␤ (N-42) polyclonal antiserum samples or the purity and solubility of the peptides used as calibrators (8 ) . The sensitivity of an ELISA depends largely on the binding characteristics of the antigen, which may vary with temperature and buffer solutions, or among different reagent lots (6 ) . In addition, the affinity of the antibodies used in the assays might vary for the various A␤ 42 peptides involved in the pathogenesis of AD, including oligomers of the A␤ 42 peptide. A future study exchanging calibrators and antibodies among various ELISAs is necessary for harmonization.
ROC curve analysis revealed no difference in the ability of the 2 assays to differentiate AD patients from controls. In addition to the C-terminal heterogeneity, various Nterminally truncated peptides are found in the A␤ pools (19, 20 ) . These peptides are considered to play a role in the increased A␤ 42 production in developing AD. We speculate that A␤ (1-42) and A␤ (N-42) concentrations go hand in hand at a certain stage of disease, in mild to moderate AD as well as in controls. Because N-terminally truncated A␤ 42 peptides can be demonstrated early in the disease process (9 ), they might be promising markers for the preclinical diagnosis of AD, when used simultaneously with A␤ (1-42) (21 ) . Several authors found decreased A␤ (1-42) in CSF from a subset of FTLD patients (3, 22 ) . Very little information is available about the CSF A␤ (N-42) concentration in FTLD (17 ) . The reason for a decrease in CSF A␤ in FTLD is unknown, although there might be a relationship with the presence of an ⑀4 allele or with age (23 ). Interestingly, a few studies have shown the involvement of 3 mutations in the presenilin 1 gene (PSEN1) in familial forms of FTLD (24 -26 ) . These possible "loss of function" PSEN1 mutations might act as inhibitors of the ␥-secretase cleavage of APP (27 ) , leading to a decrease of A␤ (1-42) in the brain. Although most FTLD patients included in our study had the sporadic form of FTLD, we cannot exclude the possibility of a mutation in the PSEN1 gene in some of them.
